Mercy BioAnalytics has filed a notice of an exempt offering of securities to raise $41,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Mercy BioAnalytics is raising $41,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Dawn Mattoon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Mercy BioAnalytics
Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages.
To learn more about Mercy BioAnalytics, visit http://www.mercybio.com/
Contact:
Dawn Mattoon, Chief Executive Officer
480-540-5566
https://www.linkedin.com/in/dawn-mattoon-792511a/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.